OVA-specific T-cell responses underlie failure of MII.OVA engraftment. (A) CD45.1+ 11c.OVA or non-transgenic littermate controls were irradiated (300 cGy) and BM (107) from non-Tg (C57Bl/6) or MII.OVA mice injected intravenously. Six weeks later donor leukocytes were enumerated in peripheral blood. (B) B6.SJL (CD45.1+) mice were administered anti-CD4 and anti-CD8, anti-NK1.1 or isotype mAbs, irradiated (300 cGy) and BM (107) from MII.OVA mice injected intravenously. An additional dose of anti-CD4 and anti-CD8 mAb was administered 3 weeks after BM transfer. Six weeks after BMT donor leukocytes were enumerated in peripheral blood. (C) B6.SJL (CD45.1+) mice were irradiated (300 cGy) and BM (107) from non-Tg (C57Bl/6), 11c.OVA, MII.OVA, and actin.OVA mice injected intravenously. Six weeks later donor HPC (lin−c-kit+) were enumerated in BM. (D) B6.SJL (CD45.1+) mice were irradiated (300 cGy) and sorted lin−c-kit+ HPCs (2 × 105) from non-Tg (C57Bl/6), 11c.OVA or MII.OVA mice injected intravenously. Six weeks later donor leukocytes were enumerated in peripheral blood. Data represent individual mice pooled from a minimum of 2 experiments.
